Conference Coverage

Tool predicts lymphoma, death in primary Sjögren’s syndrome patients


 

FROM THE EULAR CONGRESS 2014

Since the analysis of these 921 patients was completed in January 2013, an additional 124 patients with primary SS have joined the cohort. In this larger cohort, baseline ESDAI score of 14 or higher and presence of more than one laboratory marker (lymphopenia, low cryoglobulins, hypocomplementemia, and monoclonal band) both were significantly associated with SS-related death.

Dr. Brito Zerón noted that the investigators have not analyzed whether treatment influenced outcomes in the cohort, but they plan to.

The investigators had no financial disclosures.

Pages

Recommended Reading

All glucocorticoids linked to increased risk of VTE
MDedge Hematology and Oncology
Malignancies in lupus demand clinical caution
MDedge Hematology and Oncology
Polymyalgia rheumatica carries postdiagnosis cancer risk
MDedge Hematology and Oncology
Opioid overdose deaths skyrocket in women
MDedge Hematology and Oncology
Exercise dampens aromatase inhibitor–related joint pain
MDedge Hematology and Oncology
No survival benefit to bisphosphonate in chemoresistant breast cancer
MDedge Hematology and Oncology
FDA: Stop prescribing combo drugs with high-dose acetaminophen
MDedge Hematology and Oncology
VIDEO: Practice pearls for treating opiate dependence
MDedge Hematology and Oncology
Nonmelanoma skin cancer linked to increased fracture risk in postmenopausal women
MDedge Hematology and Oncology
VIDEO: Goserelin helps dodge ovarian failure in HR-negative breast cancer
MDedge Hematology and Oncology